Acadia Pharmaceuticals (ACAD) Raw Materials (2016 - 2026)

Acadia Pharmaceuticals has reported Raw Materials for 11 years, with the latest figure at $74.3 million in Q1 2026.

• For the quarter ending Q1 2026, Raw Materials fell 2.84% year-over-year to $74.3 million; the trailing twelve-month figure through Mar 2026 stood at $74.3 million (down 2.84% YoY), and the FY2025 full-year result was $82.8 million, up 18.7% from the prior year.
• Raw Materials for Q1 2026 stood at $74.3 million, down from $82.8 million in the prior quarter.
• The five-year high for Raw Materials was $83.7 million in Q2 2025, with the low at $5.2 million in Q1 2023.
• Average Raw Materials over 5 years is $41.6 million, with a median of $42.2 million recorded in 2024.
• Year-over-year, Raw Materials declined 16.62% in 2023 and surged 934.36% in 2024.
• Tracing ACAD's Raw Materials over 5 years: stood at $5.2 million in 2022, then surged by 501.34% to $31.3 million in 2023, then soared by 122.73% to $69.7 million in 2024, then gained by 18.7% to $82.8 million in 2025, then slipped by 10.21% to $74.3 million in 2026.
• The last three Raw Materials figures came in at $74.3 million (Q1 2026), $82.8 million (Q4 2025), and $77.8 million (Q3 2025), per Business Quant data.

Peer Comparison